AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12612903
Drug: Interferon alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa‐2b (3 MU 3 times a week) plus 1000‐1200 mg/day ribavirin for 1 year
Trial: 10234597
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg daily by mouth
Trial: 25641533
Drug: Heparin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin and glycoprotein IIb/IIIa inhibitor
Trial: 23425430
Drug: Fixed-combination brinzolamide
RxNorm normalized name: Brinzolamide
DrugBank: Brinzolamide (DB01194)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fixed-combination brinzolamide 1%/brimonidine 0.2% (BBFC)
Trial: 21271174
Drug: Sufentanil (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (0.1 µg/kg)
Trial: 21271174
Drug: Clonidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.5 µg/kg)
Trial: 9671875
Drug: Goserelin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin plus antiandrogen therapy
Trial: 9671875
Drug: Leuprolide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide plus antiandrogen therapy
Trial: 9671875
Drug: Leuprolide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide plus flutamide therapy
Trial: 9671875
Drug: Goserelin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin plus bicalutamide therapy
Trial: 9671875
Drug: Goserelin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin plus flutamide therapy
Trial: 9671875
Drug: Leuprolide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide plus bicalutamide therapy
Trial: 8044010
Drug: Xijian Tongshuan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xijian Tongshuan pill (XJTS)
Trial: 8044010
Drug: Cyclandelate capsule
RxNorm normalized name: Cyclandelate
DrugBank: Cyclandelate (DB04838)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclandelate capsule (Control group B)
Trial: 25720929
Drug: FUSION BIOLINE
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FUSION BIOLINE heparin-coated vascular graft
Trial: 17304149
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg daily for 6 days
Trial: 15085466
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous unfractionated heparin (UFH) for 5 days
Trial: 2863541
Drug: Warfarin for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin for 3 months
Trial: 16871061
Drug: Oral feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral feedback
Trial: 11499187
Drug: Any feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any feedback (oral or written)
Trial: 7840913
Drug: Saquinavir 200
RxNorm normalized name: saquinavir 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir 200 mg in combination with zidovudine
Trial: 25922420
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg oral MDMA
Trial: 17578566
Drug: ATP (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATP (2 g per dosage)
Trial: 17578566
Drug: Adenosine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (1 g per dosage)
Trial: 14760130
Drug: Palonosetron (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron (various doses)
Trial: 11123827
Drug: Weekly doses
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly doses of 400 mg of ferrous sulphate for 4 months
Trial: 3881376
Drug: Adjuvant MOPP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant MOPP chemotherapy
Trial: 3881376
Drug: New mild
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New mild adjuvant chemotherapy VBM (vinblastine, bleomycin, and methotrexate) with ABVD in combined modality and alternating regimens
Trial: 22126423
Drug: Alfacalcidol (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol (0.03 µg/kg/day) - Monotherapy
Trial: 22126423
Drug: Alfacalcidol and
RxNorm normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol and Risedronate (0.05 mg/kg/day) - Polytherapy
Trial: 22126423
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (discontinued medications)
Trial: 11913800
Drug: E 047/1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E 047/1 (1 mg kg(‐1) in pilot study, 2 mg kg(‐1) or 3 mg kg(‐1) bolus in randomized trial)
Trial: 9653596
Drug: Sex hormone
RxNorm normalized name: Sex hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sex hormone replacement with 17 beta‐estradiol and norethisterone
Trial: 8595637
Drug: Ibuprofen lysine
RxNorm normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen lysine 400 mg
Trial: 2475016
Drug: Prazosin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (2 mg twice daily)
Trial: 26239241
Drug: Self-administered Internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered Internet-based intervention protocol (SII)
Trial: 30268162
Drug: Aloe Vera
RxNorm normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloe Vera gel
Trial: 1727882
Drug: 1% silver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% silver sulfadiazine cream
Trial: 29080520
Drug: Chamomile therapy
RxNorm normalized name: Chamomile
DrugBank: Chamomile (DB14357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chamomile therapy
Trial: 27172423
Drug: Weekly distributed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly distributed bronchoscopy simulation practice
Trial: 16554683
Drug: Level 1
RxNorm normalized name: PALFORZIA (Level 10) KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Level 1 treatment studies in traumatic brain injury (15 studies)
Trial: 16554683
Drug: Level 1
RxNorm normalized name: PALFORZIA (Level 10) KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Level 1 treatment studies in burn rehabilitation (12 studies)
Trial: 16554683
Drug: Level 2
RxNorm normalized name: True Metrix Control Level 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Level 2 treatment studies in spinal cord injury (26 studies)
Trial: 16554683
Drug: Level 2
RxNorm normalized name: True Metrix Control Level 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Level 2 treatment studies in traumatic brain injury (4 studies)
Trial: 16554683
Drug: Level 2
RxNorm normalized name: True Metrix Control Level 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Level 2 treatment studies in burn rehabilitation (2 studies)
Trial: 14627846
Drug: Haloperidol (subchronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (subchronic low dose)
Trial: 14627846
Drug: Haloperidol (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (higher dose)
Trial: 7282603
Drug: 4.1 g
RxNorm normalized name: psyllium 4.1 GM Powder for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.1 g omega 3 fatty acids
Trial: 7282603
Drug: 8.2 g
RxNorm normalized name: SORBITOL 258.2 g in 474 mL ORAL SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8.2 g omega 3 fatty acids
Trial: 29368994
Drug: Message to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Message to avoid antipsychotic medications
Trial: 29368994
Drug: Actual facility
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Actual facility antipsychotic prevalence
Trial: 29368994
Drug: Avoid antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avoid antipsychotics message
Trial: 15561516
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine treatment for 4 weeks
Trial: 15561516
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list control group (continued previous headache treatment)
Trial: 15561516
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine treatment
Trial: 17932848
Drug: Chloramphenicol 0.25%-betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloramphenicol 0.25%-betamethasone 0.13% gel three times a day (Group 1)
Trial: 16249353
Drug: Paclitaxel (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (200 mg/m² i.v. day 1), carboplatin (AUC 6 i.v. day 1), and etoposide (50 mg/100 mg alternating daily by mouth days 1-10) every 21 days
Trial: 9952060
Drug: 0.30 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.30 g/kg ethanol
Trial: 9952060
Drug: 0.60 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.60 g/kg ethanol
Trial: 25711322
Drug: HIV RNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV RNA <50 copies/mL
Trial: 25711322
Drug: HIV RNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV RNA between 51 and 400 copies/mL
Trial: 25711322
Drug: HCV antibody
RxNorm normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV antibody positivity
Trial: 17349088
Drug: n-3-enriched foods
RxNorm normalized name: 3-n-butylphthalide
DrugBank: Butylphthalide (DB12749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3-enriched foods (EPA + DHA intake of 1 g/d)
Trial: 10993128
Drug: Sertraline (50-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50-200 mg)
Trial: 19160529
Drug: Simvastatin 20-40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20-40 mg/day
Trial: 14656784
Drug: Fentanyl 50
RxNorm normalized name: fentanyl 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 50 micro g, lockout six‐minute
Trial: 14656784
Drug: Fentanyl 25
RxNorm normalized name: FENTANYL 25MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 25 micro g, lockout three‐minute
Trial: 14656784
Drug: Fentanyl 50
RxNorm normalized name: fentanyl 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 50 micro g, lockout three‐minute
Trial: 24445560
Drug: Morphine PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine PCA
Trial: 1399944
Drug: RP 59500
RxNorm normalized name: RP-72
DrugBank: RP-72 (DB17156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP 59500 (1.4, 2.8, 4.6, 7.0, 9.8, 12.6, 16.8, 22.4, 29.4 mg/kg)
Trial: 6235453
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (Heptavax‐B), 40 micrograms each, administered in three doses.
Trial: 6235453
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (Heptavax‐B).
Trial: 31049735
Drug: Different food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different food formulations and processing methods involving meat, wholegrain, fruits and vegetables
Trial: 19780244
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy with alkylating agent-based therapies
Trial: 8195454
Drug: Flutamide (nonsteroidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (nonsteroidal androgen receptor blocking agent)
Trial: 2884455
Drug: Bovine rotavirus
RxNorm normalized name: human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension [RotaTeq]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine rotavirus vaccine (RIT 4237), 3 doses administered concurrently with oral or killed polio vaccine.
Trial: 2884455
Drug: Placebo/oral polio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/oral polio group (unvaccinated control).
Trial: 2884455
Drug: Concurrent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent administration of oral polio vaccine with rotavirus vaccine.
Trial: 2884455
Drug: Oral polio
RxNorm normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral polio and rotavirus vaccines.
Trial: 23392654
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (aspirin and clopidogrel)
Trial: 18342111
Drug: Avène thermal
RxNorm normalized name: avens extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avène thermal spring water anti burning gel (ATSW gel)
Trial: 18342111
Drug: Trolamine cream
RxNorm normalized name: METHYL SALICYLATE/TROLAMINE CREAM
DrugBank: Trolamine (DB13747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trolamine cream (Control)
Trial: 1381822
Drug: Other antiarrhythmic
RxNorm normalized name: Other antiarrhythmics, class I and III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antiarrhythmic drugs
Trial: 21114406
Drug: NuLytely(®) (PEG‐3350,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NuLytely(®) (PEG‐3350, sodium chloride, sodium bicarbonate, and potassium chloride solution)
Trial: 17689667
Drug: Internet-administered Edinburgh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-administered Edinburgh Depression Scale (EDS)
Trial: 10773774
Drug: Weekly group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly group psychotherapy for 4 months
Trial: 29803904
Drug: Ixekizumab (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab (160 mg at week 0, 80 mg every 2 weeks up to week 12, and 80 mg every 4 weeks thereafter)
Trial: 29803904
Drug: Ixekizumab (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab (after switching from other treatments)
Trial: 25726428
Drug: Resistance exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance exercise program + 10 g/day BCAA supplementation
Trial: 25369174
Drug: Korean red
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean red ginseng (KRG) extract, 1g KRG extract/pouch, twice a day
Trial: 30314452
Drug: Extended endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended endocrine therapy to 10 years in postmenopausal subgroup
Trial: 30314452
Drug: Extended endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended endocrine therapy to 10 years in ER+ and/or PR+ subgroup
Trial: 9286780
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 infusion
Trial: 1983321
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg o.m.)
Trial: 10594396
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg b.d.)
Trial: 17237648
Drug: Long duration,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long duration, high flow rate MUF (group L)
Trial: 14725516
Drug: Synacthen Depot
RxNorm normalized name: Synacthen Depot
DrugBank: Tetracosactide (DB01284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synacthen Depot 1 mg (1 ml)
Trial: 9720545
Drug: Topical urethral
RxNorm normalized name: Urethral Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical urethral anesthesia with adjunctive intravenous sedoanalgesia
Trial: 9720545
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Topical anesthesia and Sedoanalgesia)
Trial: 8158032
Drug: Mefloquine prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine prophylaxis (10 mg/kg initial loading dose)
Trial: 3377147
Drug: Intramuscular papaveretum
RxNorm normalized name: papaveretum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular papaveretum 0.2 mg/kg
Trial: 3377147
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication (placebo)
Trial: 23446073
Drug: Biofeedback-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback-based cognitive-behavioral treatment (BFB-CBT)
Trial: 9773111
Drug: Diltiazem (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (300 mg)
Trial: 8196120
Drug: OspA Lyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OspA Lyme vaccine (10 micrograms, 2 doses)
Trial: 8196120
Drug: OspA Lyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OspA Lyme vaccine adsorbed to alum (10 micrograms, 2 doses)
Trial: 31690121
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection with 1% lidocaine and epinephrine (1 mL, 40 mg triamcinolone + 1 mL lidocaine with epinephrine)
Trial: 27106967
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TA) 4 g over 1 h, then 1 g per h over six h
Trial: 24504445
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD) 45 mg/m² every 4 weeks
Trial: 24504445
Drug: Capecitabine 1000
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m² twice daily, day 1-14 every 3 weeks
Trial: 22776045
Drug: CC with
RxNorm normalized name: BD Syringe 5cc with Needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC with a bolus calculator
Trial: 20660038
Drug: 1 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg cosyntropin test
Trial: 18486512
Drug: Baseline alanine
RxNorm normalized name: Alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baseline alanine aminotransferase (ALT) levels of 17-22 mg/dl
Trial: 18486512
Drug: Baseline alanine
RxNorm normalized name: Alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baseline alanine aminotransferase (ALT) levels of 23-38 mg/dl
Trial: 18486512
Drug: Baseline alanine
RxNorm normalized name: Alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baseline alanine aminotransferase (ALT) levels greater than 38 mg/dl
Trial: 16133900
Drug: Project SPORT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Project SPORT (brief consultation and prescription with a mailed reinforcing follow-up flyer)
Trial: 12471182
Drug: Alteplase (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase (2 mg/2 mL) administered into the lumen of the central venous catheter, with a maximum of two doses allowed to dwell for up to 120 minutes each.
Trial: 2106087
Drug: Dexamethasone (Dex)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (Dex) 4 mg i.v. administered 3 h before GHRH
Trial: 2106087
Drug: Clonidine administration
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine administration 300 micrograms p.o. with Dex 8 mg
Trial: 2106087
Drug: Clonidine administration
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine administration 300 micrograms p.o. with Dex 22 mg
Trial: 17324283
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care approach including contracting, 'Problem Solving Treatment', antidepressant algorithm, and manual-guided self-help
Trial: 2511802
Drug: Fleroxacin 600
RxNorm normalized name: fleroxacin
DrugBank: Fleroxacin (DB04576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 600 mg once daily for 7 days
Trial: 2511802
Drug: Fleroxacin 800
RxNorm normalized name: fleroxacin
DrugBank: Fleroxacin (DB04576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 800 mg once daily for 7 days
Trial: 2511801
Drug: Fleroxacin 800
RxNorm normalized name: fleroxacin
DrugBank: Fleroxacin (DB04576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 800 mg
Trial: 337916
Drug: Three-drug regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug regimen (cyclophosphamide, methotrexate, fluorouracil)
Trial: 337916
Drug: Five-drug regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-drug regimen (vincristine sulfate, prednisone, cyclophosphamide, methotrexate, fluorouracil)
Trial: 337916
Drug: Five-drug regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-drug regimen after progression of disease
Trial: 25035069
Drug: SFC 50/250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFC 50/250 μg Rotacaps/Rotahaler (S)
Trial: 25035069
Drug: SFC 50/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFC 50/100 μg Rotacaps/Rotahaler (L)
Trial: 25035069
Drug: SFC at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFC at both doses and via both inhalers